Cutaneous Small-vessel Vasculitis after ChAdOx1 COVID-19 Vaccination: A Report of Five CasesChAdOx1 COVID-19 예방접종 후 피부 소혈관염: 5건의 보고Case Reports Published on 2022-06-012022-09-11 Journal: The international journal of lower extremity wound [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome adverse event Affect Antihistamines arteries Arterioles Autoimmunity Capillaries ChAdOx1 ChAdOx1 COVID-19 vaccine clinician coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination Cutaneous Cutaneous Small-vessel Vasculitis defined demonstrated detectable FIVE lesion lower limb lower limbs Methylprednisolone one patient organs pandemic Pathogenesis Patient pregnant women reaction report reported required SARS-CoV-2 Severe acute respiratory syndrome small blood vessels South Korea spread to Steroids Symptom upper limb upper limbs vaccination Vasculitis women [DOI] 10.1177/15347346221078734 PMC 바로가기 [Article Type] Case Reports
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial이종 ChAdOx1/BNT162b2 예방 접종은 동종 ChAdOx1 예방 접종보다 더 강한 면역 반응을 유도합니다. 실용적인, 다기관, 3군, 부분 무작위 HEVACC 시험Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] 1:1 adaptive antibody Antibody titer Antibody titers approved Arm AstraZeneca B.1.617.2 BNT BNT162b2 breath ChAdOx1 comparable conducted COVID-19 COVID-19 vaccine Delta effective first dose Frequency group groups Heterologous Heterologous COVID-19 vaccination homologous immune response immunized immunogenicity induce interim analysis less median mRNA vaccine mRNA vaccines Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers NIAID participant Pfizer Pfizer/BioNTech Pragmatic primary endpoint Randomized reactogenicity regimen response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants severe adverse events spike-specific T cell statistically significant stratified by sex supported T cell T cell responses T cells Trial university vaccination vaccination schedule Vaccine vaccinees Vaccines [DOI] 10.1016/j.ebiom.2022.104073 PMC 바로가기 [Article Type] Randomized Controlled Trial
Humoral and Cellular Responses to BNT162b2 as a Booster Following Two Doses of ChAdOx1 nCov-19 Determined Using Three SARS-CoV-2 Antibody Assays and an Interferon-Gamma Release Assay: A Prospective Longitudinal Study in Healthcare Workers세 가지 SARS-CoV-2 항체 분석 및 인터페론-감마 방출 분석을 사용하여 결정된 2회 용량의 ChAdOx1 nCov-19 후 부스터로서의 BNT162b2에 대한 체액 및 세포 반응: 의료 종사자에 대한 전향적 종단 연구Article Published on 2022-06-012022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abbott Adverse reactions antibody antibody assay Antibody titer assay BNT162b2 booster booster dose booster vaccination Booster vaccine cellular response Cellular responses ChAdOx1 ChAdOx1 nCoV-19 collected contribute coronavirus disease determine dose Genscript healthcare humoral IgG INF-γ information interferon-γ Laboratory longitudinal longitudinal change median Mild MOST Neutralizing antibodies neutralizing antibody participant Participants positive Prospective provide Quantitative questionnaire Release reported response Roche SARS-CoV-2 second dose significantly increased Spread vaccination Vaccine worker [DOI] 10.3389/fimmu.2022.859019 PMC 바로가기 [Article Type] Article
Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2동종 CoronaVac 또는 ChAdOx1을 사용한 백신 접종 및 BNT162b2를 사용한 이종 3차 접종에 대한 체액 및 세포 반응Comment Published on 2022-06-012022-09-12 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract antibodies BNT162b2 booster cellular response ChAdOx1 CoronaVac COVID-19 dose Heterologous homologous Interferon-gamma Neutralizing SARS-CoV-2 vaccination Vaccine [DOI] 10.1016/j.jinf.2022.02.026 PMC 바로가기 [Article Type] Comment
Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study델타 변이체(B.1.617.2) 및 스코틀랜드 환자의 2차 접종 이후 경과 시간(REACT-SCOT)과 관련된 중증 COVID-19에 대한 백신 효능: 사례-대조군 연구Article Published on 2022-06-012022-09-11 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, [키워드] 95% CI age Alpha Analysis ascertainment bias B.1.1.7 B.1.617.2 booster doses Case-control case-control study ChAdOx1 ChAdOx1 vaccine classification coded community health Control controls COVID-19 Critical care database death declined decrease defined delta variant diagnosed dose Efficacy expected first positive Follow-up hospitalisation include index measure Moderna mRNA mRNA vaccine mRNA vaccines not limited outcome Patient Pfizer predominant presenting primary care primary outcome measure Protective replaced replacement report reported reversed risk SARS-CoV-2 variant Scottish second dose selected Severe case severe cases severe COVID-19 severe disease severity Sex study period suggested Support transmission rate transmission rates vaccination Vaccine vaccine efficacy Vaccines variant [DOI] 10.1016/S2213-2600(22)00045-5 PMC 바로가기 [Article Type] Article
First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence1세대 BNT162b2 및 AZD1222 백신은 오미크론 변이체가 출현하는 동안 COVID-19 폐렴으로부터 보호합니다Article Published on 2022-06-012022-09-11 Journal: Public health [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI 95% confidence interval administration analyses analyzed Arterial hypertension AZD1222 B.1.1.529 BNT162 vaccine BNT162b2 ChAdOx1 ChAdOx1 nCoV-19 CIs Comorbidity conducted coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia diabetes Diabetes Mellitus disease elapsed evaluated Factor Gender greater higher risk hypertension identify illness onset Immunosuppression increased risk increasing age individual individuals Kidney disease linear models Manifestations nCoV Obstructive omicron Omicron variant Pneumonia pneumonia case pneumonia cases PROTECT protective effect reduce retrospective cohort study risk risk of COVID-19 risk ratio risk ratios RRs SARS-CoV-2 variants smoking subject type 2 diabete Type 2 diabetes mellitus Vaccine variant [DOI] 10.1016/j.puhe.2022.04.001 PMC 바로가기 [Article Type] Article
Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort studyObservational Study Published on 2022-05-312022-10-05 Journal: BMC Infectious Diseases [Category] Coronavirus, 임상, [키워드] adjusted Adverse Adverse drug reaction age age and sex AstraZeneca BNT162b2 boost ChAdOx1 Cohort comparable Complete COVID-19 dose Efficacy Factor Frequency Gender Health Heterologous homologous immunization individual Moderna mRNA vaccine mRNA-1273 mRNA-vaccine mRNA-vaccines Observational cohort study observational study pandemic participant problem proportion reaction reactogenicity regimen regimens reported resource survey vaccination Vaccines were assessed with COVID-19 [DOI] 10.1186/s12879-022-07443-x PMC 바로가기 [Article Type] Observational Study
Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including OmicronBNT162b2 및 ChAdOx1 nCoV-19 백신 접종은 Omicron을 포함한 SARS-CoV-2 변이체에 대한 교차 반응성 항-RBD IgG를 유도합니다Article Published on 2022-05-282022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, 치료법, [키워드] adaptive Adaptive immunity age Alpha Alpha variant anti-RBD BNT162b2 booster vaccinations Breakthrough infection breakthrough infections caused ChAdOx1 ChAdOx1 nCoV-19 Cohort contribute Course COVID-19 cross-reactive cross-reactive antibodies cross-reactivity Delta delta variant domain ELISA explain Gamma health-care IgG IgG ELISA IgG level IgG levels Immunity independent independent of individual Infection infection rate lethality magnitude morbidity nucleocapsid nucleocapsid IgG omicron Omicron variants RBD RBD IgG reactivity Receptor-binding domain Receptor-binding domain (RBD) recipient SARS-CoV-2 SARS-CoV-2 testing SARS-CoV-2 variants sera Sex significant increase significantly higher significantly lower Spike protein Spread tested the spike protein university vaccination vaccination rate Vaccine variants variants of concern Vienna VoC VOCs was increased while [DOI] 10.3390/v14061181 PMC 바로가기 [Article Type] Article
Adequacy of Hemodialysis Serves as an Independent Predictor of Humoral Response to ChAdOx1 Prime-Boost Vaccination in Hemodialysis Patients혈액 투석의 적절성은 혈액 투석 환자의 ChAdOx1 프라임 부스트 백신 접종에 대한 체액 반응의 독립적인 예측 인자로 작용합니다Article Published on 2022-05-262022-09-12 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 1.26 acute respiratory syndrome Adequacy analyzed ANOVA antibody applied ChAdOx1 coronavirus correlation COVID-19 COVID-19 vaccine dialysis domain dose enrolled enzyme-linked immunosorbent evaluate geometric mean titer healthy control healthy subject Hemodialysis hemodialysis adequacy Multiple linear regression neutralization neutralization titer Neutralizing Neutralizing antibodies neutralizing antibody Oxford-AstraZeneca parameter Patient predict predictor Prospective Study quantification regression analysis response Seroconversion seronegative seropositive subject the spike protein vaccination Vaccine [DOI] 10.3390/v14061149 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVacCoronaVac을 투여받은 성인에서 피내 경로를 통한 AZD1222의 추가 투여 후 면역원성 및 반응성Article Published on 2022-05-262022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95%CI administration anti-S anti-SARS-CoV-2 IgG Anti-spike antibody Antibody Response Antibody responses Antibody titer AstraZeneca AZD1222 Blister booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine cohort study common completion CoronaVac CoronaVac vaccine COVID-19 vaccine COVID-19 vaccines delta variant determine dose Endpoint Erythema evaluated geometric geometric mean geometric mean ratios GMRs healthy IgG immunogenicity Immunoglobulin Immunoglobulin G immunologic response injection Intradermal Local median age neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer occurred participant participated primary endpoint proportion prospective cohort study RBD IgG reactogenicity recipient reported resource SARS-CoV-2 vaccine surrogate virus neutralization test sVNT systemic reactogenicity variant Viral Virus neutralization was collected wild type [DOI] 10.1016/j.vaccine.2022.04.067 PMC 바로가기 [Article Type] Article